Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Consolidated Net Income (2016 - 2026)

Ani Pharmaceuticals' Consolidated Net Income history spans 15 years, with the latest figure at $27.5 million for Q4 2025.

  • On a quarterly basis, Consolidated Net Income rose 367.86% to $27.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $78.4 million, a 523.07% increase, with the full-year FY2025 number at $78.3 million, up 522.94% from a year prior.
  • Consolidated Net Income hit $27.5 million in Q4 2025 for Ani Pharmaceuticals, up from $26.6 million in the prior quarter.
  • Over the last five years, Consolidated Net Income for ANIP hit a ceiling of $27.5 million in Q4 2025 and a floor of -$24.2 million in Q3 2024.
  • Historically, Consolidated Net Income has averaged -$590600.0 across 5 years, with a median of -$1.1 million in 2021.
  • Biggest five-year swings in Consolidated Net Income: plummeted 18370.0% in 2022 and later skyrocketed 1135.21% in 2024.
  • Tracing ANIP's Consolidated Net Income over 5 years: stood at -$24.1 million in 2021, then soared by 82.24% to -$4.3 million in 2022, then skyrocketed by 126.99% to $1.2 million in 2023, then crashed by 989.7% to -$10.3 million in 2024, then surged by 367.86% to $27.5 million in 2025.
  • Business Quant data shows Consolidated Net Income for ANIP at $27.5 million in Q4 2025, $26.6 million in Q3 2025, and $8.5 million in Q2 2025.